Autism Spectrum Disorder (ASD) Clinical Trial
Official title:
Acceptance and Commitment Therapy Guided Self-help for Adults With a Diagnosis of Autistic Spectrum Disorder Experiencing Psychological Distress
This study aims to investigate the efficacy of guided self-help Acceptance Commitment Therapy (ACT) for adults who have a diagnosis for Autistic Spectrum Disorder (ASD) and are experiencing psychological distress (stress, anxiety or depression). This is a repeated measures design, using a single case experimental design (SCED) over a period of fourteen weeks. Each participant (n=8) with be asked to complete weekly measures and shortened measures every three days, while they read an ACT guided self-help bibliotherapy. For more information about the measures, please see outcome measure section. The ACT guided bibliotherapy will be administered to each participant on a weekly basis, over eight weeks. Participants will be asked to complete outcome measures at two week and at four weeks post intervention.
Status | Recruiting |
Enrollment | 8 |
Est. completion date | August 20, 2022 |
Est. primary completion date | January 20, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. 18+ years old with a formal diagnosis of Autistic Spectrum Disorder, without a diagnosis if an Intellectual Disability. 2. To be over the age of 18 years. 3. Accessing Nottingham City Autism Service 4. Experiencing elevated anxiety, and / or stress, and /or depression and meet the clinical threshold or moderate on the Depression, Anxiety and Stress Scale. 5. Access to the internet via an electronic device (to complete electronic measures). 6. Agreement and knowledge of the time commitment for the completion of the intervention, competition of measure and change questionnaire at the end of the study. Exclusion Criteria: 1. Unable to communicate fluently in English (justification: the cost of hiring an interpreter). 2. Unable to read English (justification: participant will be unable to read and engage in the bibliotherapy) 3. Adults who are currently accessing psychological therapy. If participants start psychological therapy during the study, they will be removed from the study (justification: unable to separate out effects of research intervention from psychological therapy intervention). 4. If they have a co-morbid diagnosis of intellectual disability (justification: may have different needs regarding therapy adaptations. 5. No access to mobile or internet (justification: unable to complete measures). |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Nottingham City Autisum Service | Nottingham | Nottinghamshire |
Lead Sponsor | Collaborator |
---|---|
University of Lincoln | Nottinghamshire Healthcare NHS Trust |
United Kingdom,
A-Tjak JG, Davis ML, Morina N, Powers MB, Smits JA, Emmelkamp PM. A meta-analysis of the efficacy of acceptance and commitment therapy for clinically relevant mental and physical health problems. Psychother Psychosom. 2015;84(1):30-6. doi: 10.1159/000365764. Epub 2014 Dec 24. — View Citation
Bruggink A., Huisman S., Vuijk R, Kraaij V, & Garnefski N. Cognitive emotion regulation, anxiety and depression in adults with autism spectrum disorder. Research in Autism Spectrum Disorders 22, 34-44, 2016
Cath DC, Ran N, Smit JH, van Balkom AJ, Comijs HC. Symptom overlap between autism spectrum disorder, generalized social anxiety disorder and obsessive-compulsive disorder in adults: a preliminary case-controlled study. Psychopathology. 2008;41(2):101-10. Epub 2007 Nov 23. — View Citation
Hayes SC, Luoma JB, Bond FW, Masuda A, Lillis J. Acceptance and commitment therapy: model, processes and outcomes. Behav Res Ther. 2006 Jan;44(1):1-25. — View Citation
Hirvikoski T, Blomqvist M. High self-perceived stress and poor coping in intellectually able adults with autism spectrum disorder. Autism. 2015 Aug;19(6):752-7. doi: 10.1177/1362361314543530. Epub 2014 Jul 29. — View Citation
Jacobson NS, Follette WC, & Revenstorf D. Psychotherapy outcome research: Methods for reporting variability and evaluating clinical significance. Behavior therapy 15(4):336-352, 1984.
Lane JD, Gast DL. Visual analysis in single case experimental design studies: brief review and guidelines. Neuropsychol Rehabil. 2014;24(3-4):445-63. doi: 10.1080/09602011.2013.815636. Epub 2013 Jul 24. Review. — View Citation
Lecavalier L. Behavioral and emotional problems in young people with pervasive developmental disorders: relative prevalence, effects of subject characteristics, and empirical classification. J Autism Dev Disord. 2006 Nov;36(8):1101-14. — View Citation
Swain J, Hancock K, Hainsworth C, Bowman J. Acceptance and commitment therapy in the treatment of anxiety: a systematic review. Clin Psychol Rev. 2013 Dec;33(8):965-78. doi: 10.1016/j.cpr.2013.07.002. Epub 2013 Jul 16. Review. — View Citation
Weston L, Hodgekins J, Langdon PE. Effectiveness of cognitive behavioural therapy with people who have autistic spectrum disorders: A systematic review and meta-analysis. Clin Psychol Rev. 2016 Nov;49:41-54. doi: 10.1016/j.cpr.2016.08.001. Epub 2016 Aug 4. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Comprehensive Assessment of Acceptance and Commitment Therapy Process (CompACT) repeated measure of change | 23 Item measure of Psychological Flexibility
The CompACT total score (out of 138). Higher scores indicate greater psychological flexibility (openness, awareness and activation) Th CompACT can also be separated into three subscales: Openness to Experince (OE) subscale (out of 60): Higher scores indicate greater openness to experience - i.e., willingness to experience internal events (thoughts, feelings, sensations, etc.) without trying to control or avoid them Behavioural Activation (BA) subscale (out of 30): Higher scores indicate greater behavioural awareness (mindful attention to current actions) Valued Action (VA) subscale (out of 48): Higher scores indicate greater engagement in valued actions (meaningful activity). |
Administered pre-intervention phase, two week and four week post intervention | |
Primary | Comprehensive Assessment of Acceptance and Commitment Therapy Process (CompACT short form) repeated measure of change | 8 Item measure of Psychological Flexibility. Scores are derived by summing responses for each of the three subscales (Openness to Experience; Behavioural Awareness; Valued Action) or the scale as a whole (CompACT Total score).
The full-scale CompACT Total score ranges from 0-48, with higher scores indicating greater psychological flexibility: The ability to attend and adapt to situational demands in the pursuit of personally meaningful longer-term goals. Openness to Experience (OE) subscale (0-18) higher scores indicating greater openness to experience (willingness to experience internal events [thoughts, feelings, sensations, etc.] without trying to control or avoid them). Behavioural Awareness (BA) subscale (0-12) higher scores indicating greater behavioural awareness (mindful attention to current actions). Valued Action (VA) subscale (0-18) with higher scores indicating greater engagement in valued actions (meaningful activity). |
Administered every three days during baseline and intervention period | |
Primary | The Depression, Anxiety and Stress Scale (DASS-21) repeated measure of change | 21 Item measure of depression, stress and anxiety
Scores for Depression, Anxiety and Stress are calculated by summing the scores for the relevant items. Recommended cut-off scores for conventional severity labels (normal, moderate, severe) are as follows: Depression: Normal 0-9, Mild 0-13, Moderate 14-20, Severe 21-27, Extremely Severe 28+ Anxiety: Normal 0-7, Mild 8-9, Moderate -14, Severe 15-19, Extremely Severe 20+ Stress: Normal 0-14, Mild 15-18, Moderate 19-25,Severe 26-33, Extremely Severe 37+ |
Administered as a screening questionaire; weekly during baseline and intervention phase, two and four weeks post intervention phase. | |
Secondary | Personal Questionnaire (PQ) repeated measure of change | 3 Item statements created by the client and based upon the clients values
The Personal Questionnaire (PQ) is an expanded target complaint measure which is individualized for each client. It intended to be a list of problems or behaviours that the client wishes to work on during the intervention, stated in the client's own words. Clients rate each question on a likert scale scale (0-5), higher scores indicating more success/achievement at the target behaviour. |
Administered once during pre-intervention phase, Two and four weeks post intervention phase | |
Secondary | World Health Organisation Quality of Life Questionnaire (WHO-QoL- BRIEF) repeated measure of change | 26 Item measure assessing Quality of Life.
The WHOQOL-BREF produces a quality of life profile. It is possible to derive four domain scores; physical health (out of 35), psychological (out of 30), social relationships (out of 15) and environment (out of 40). There are also two items that are examined separately: question 1 asks about an individuals overall perception of quality of life and question 2 asks about an individuals overall perception of their health. The four domain scores denote an individuals perception of quality of life in each particular domain. Domain scores are scaled in a positive direction (i.e. higher scores denote higher quality of life). |
Administered pre-intervention, weekly during baseline and intervention phase, two and four week post intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03715166 -
Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder
|
Phase 3 | |
Not yet recruiting |
NCT05182697 -
SCI-210 in the Treatment of Children and Young Adults With AutismEvaluate the Safety, Tolerability and Efficacy of SCI-210 in Children With Autism Spectrum Disorder (ASD)
|
N/A | |
Completed |
NCT02803801 -
Build Your Parenting Toolkit: Guiding Children to Become Flexible Thinkers
|
N/A | |
Terminated |
NCT03715153 -
Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.
|
Phase 3 | |
Terminated |
NCT01592773 -
Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
|
Phase 2 | |
Withdrawn |
NCT01395953 -
Double-blind Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders
|
Phase 2 | |
Terminated |
NCT01248130 -
Omega-3 Fatty Acids Monotherapy in Children and Adolescents With Autism Spectrum Disorders
|
Phase 2 | |
Completed |
NCT04860986 -
A Repeatability and Reproducibility Study of the EarliPointâ„¢ Device
|
||
Completed |
NCT04299464 -
A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD)
|
Phase 2 | |
Recruiting |
NCT03392870 -
Evaluation of a Clinical Transitional Program in Autism
|
N/A | |
Completed |
NCT01592786 -
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
|
Phase 2 | |
Enrolling by invitation |
NCT05187377 -
A Controlled Trial of Growth Hormone in Phelan-McDermid Syndrome and Idiopathic Autism
|
Phase 2 | |
Completed |
NCT04631432 -
Choice Switching and Autism
|
||
Recruiting |
NCT04578756 -
Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder
|
Phase 3 | |
Recruiting |
NCT06443320 -
Evaluation of the Videodrama Therapeutic Device for Children With Autism Spectrum Disorders
|
N/A | |
Completed |
NCT02037022 -
Pivotal Response Treatment Package for Young Children With Autism
|
N/A | |
Completed |
NCT01854346 -
Social Skills Group Training ("KONTAKT") for Children and Adolescent With High-functioning Autism Spectrum Disorders
|
N/A | |
Active, not recruiting |
NCT04895215 -
AB-2004 in Treatment of Irritability Associated With Autism Spectrum Disorder (ASD)
|
Phase 2 | |
Active, not recruiting |
NCT03426826 -
The Gut-Brain Study
|
Phase 1 | |
Completed |
NCT02384486 -
Efficacy of Training Programme to Reduce Stress
|
N/A |